Ebola virus (EBOV) disease outbreaks, as well as the ability of EBOV to persist in the environment under certain conditions, highlight the need to develop effective decontamination techniques against the virus. We evaluated the efficacy of hydrogen peroxide vapor (HPV) to inactivate MS2 and Phi6 bacteriophages, the latter a recommended surrogate for EBOV.  https://www.selleckchem.com/products/lee011.html  The phages were inoculated onto six material types with and without the presence of whole human blood. The inoculated materials were then exposed to either a high or low concentration of HPV for various elapsed times. The phages were also recovered from positive controls at these same elapsed times, to assess environmental persistence and decontamination efficacy. Low concentration hydrogen peroxide vapor (LCHP; 25 ppm) was effective against both phages on all materials without the presence of blood at 2 h. LCHP was ineffective against the phages in the presence of blood, on all materials, even with a 3-day contact time. Higher concentrations of HPV (>400 ppm) with contact times of 24-32 h achieved approximately 2-6 log reduction of the phages in the presence of blood.A commercial blend of mainly carnallite (KCl·MgCl2·6H2O) is considered as a next-generation heat transfer fluid in solar thermal plants. Corrosive properties of MgCl2 hydrates must be addressed at the operating temperatures of 500-720 °C. For successful chemical monitoring of the carnallite heat transfer fluid, an experimental method was developed to separate and titrate for MgO and MgOHCl from solid carnallite. This new method was assessed for error and accuracy. The method's relative error for MgOHCl was -7.0% for a mass fraction of 9.0 wt % MgOHCl in the carnallite salt. The method's relative error for MgO was less than +1.0% for a mass fraction of 12.0 wt % MgO in the carnallite salt. Titration results were used to track changes in the MgOHCl concentration in carnallite salt through the carnallite's dehydration and purification.In spite of recent developments in mass spectrometry imaging techniques, high-resolution multiplex protein bioimaging techniques are required to unveil the complex inter- and intracellular biomolecular interactions for accurate understanding of life phenomena and disease mechanisms. Herein, we report multiplex protein imaging with secondary ion mass spectrometry (SIMS) using metal oxide nanoparticle (MONP)-conjugated antibodies with less then 300 nm spatial resolution in the low ion dose without ion beam damage because of the high secondary ion yields of the MONPs, which can provide simultaneous imaging of several proteins, especially from cell membranes. We applied our new imaging technique for the study of hippocampal tissue samples from control and Alzheimer's disease (AD) model mice; the proximity of protein clusters in the hippocampus CA1 region showed intriguing dependence on aging and AD progress, suggesting that protein cluster proximity may be helpful for understanding pathological pathways in the microscopic cellular level.There is a pressing need for high-rate cycling and cost-effective stationary energy storage systems in concomitance with the fast development of solar, wind, and other types of renewable sources of energy. Aqueous rechargeable Ca-ion batteries have the potential to meet the growing demands of stationary energy storage devices because they are abundant and safe; they can also be manufactured at a low-cost and have a higher volumetric capacity. In this study, we have demonstrated a low-cost, safe, aqueous Ca-ion battery that is based on a low potential, lower specific weight, in situ polymerized polyaniline as an anode, and a high redox-potential open-framework structured potassium copper hexacyanoferrate as a cathode. The charge-discharge mechanism of this battery includes doping/dedoping of NO3- at the anode, and intercalation and deintercalation of Ca-ion at the cathode. This Ca-ion battery works successfully in a 2.5 M Ca(NO3)2 aqueous electrolyte that exhibits 70 Wh kg-1 specific energy at 250 W kg-1 and even maintains a high energy density of 53 Wh kg-1 at a higher rate of 950 W kg-1; this indicates a good rate capability (calculation based on anode active mass). At 0.8 A g-1, the battery provides an average specific capacity of 130 mA h g-1, exhibiting high Coulombic efficiency (∼96%), with 95% capacity retention of over 200 cycles across its life span, which is a new achievement in the electrochemical performance of aqueous Ca-ion batteries. Furthermore, the calcium-ion storage mechanism is investigated using high-end X-ray absorption near edge structure (XANES) and extended X-ray absorption fine structure (EXAFS) measurements. Thus, this significant electrochemical performance of the anode and the cathode renders the battery a promising candidate in grid-scale storage applications.Glioblastoma multiforme (GBM) is a grade IV astrocytoma, which is the most aggressive form of brain tumor. The standard of care for this disease includes surgery, radiotherapy and temozolomide (TMZ) chemotherapy. Poor accumulation of TMZ at the tumor site, tumor resistance to drug, and dose-limiting bone marrow toxicity eventually reduce the success of this treatment. Herein, we have encapsulated >500 drug molecules of TMZ into the biocompatible protein nanocage, apoferritin (AFt), using a "nanoreactor" method (AFt-TMZ). AFt is internalized by transferrin receptor 1-mediated endocytosis and is therefore able to facilitate cancer cell uptake and enhance drug efficacy. Following encapsulation, the protein cage retained its morphological integrity and surface charge; hence, its cellular recognition and uptake are not affected by the presence of this cargo. Additional benefits of AFt include maintenance of TMZ stability at pH 5.5 and drug release under acidic pH conditions, encountered in lysosomal compartments. MTT assays revealed that the encapsulated agents displayed significantly increased antitumor activity in U373V (vector control) and, remarkably, the isogenic U373M (MGMT expressing TMZ-resistant) GBM cell lines, with GI50 values 500 molecules of the N3-propargyl imidazotetrazine analog (N3P), developed to combat TMZ resistance, and demonstrated significantly enhanced activity of AFt-N3P against GBM and colorectal carcinoma cell lines. These studies support the use of AFt as a promising nanodelivery system for targeted delivery, lysosomal drug release, and enhanced imidazotetrazine potency for treatment of GBM and wider-spectrum malignancies.